DRF 2519

• 产品号: D6567
• 分子式: C20H18N2O5S
• 分子量: 398.43232
• 纯 度: ≥98% (HPLC)
• 保 存: under inert gas

产品别名

• 标题: DRF 2519
• IUPAC标准名: 5-({4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
• IUPAC传统名: 5-({4-[2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
• 别名: 5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione

产品登记号

• MDL号: MFCD06798336
• PubChem SID: 24894036

产品性质

• Empirical Formula (Hill Notation): C20H18N2O5S
• 纯度: ≥98% (HPLC)
• 外观: white solid
• 溶解度: DMSO: ≥10 mg/mL
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• 保存条件: under inert gas
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
DRF-2519 is a dual PPARα/γ activator. DRF-2519 has better reduction of plasma insulin, triglyceride, and free fatty acid levels than those treated with rosiglitazone.

详细说明 (简体中文)

Biochem/physiol Actions
DRF-2519 is a dual PPARα/γ activator. DRF-2519 has better reduction of plasma insulin, triglyceride, and free fatty acid levels than those treated with rosiglitazone.